From the Literature
- Adding Antiandrogen to Radiation Therapy Extends Survival in Relapsed Prostate Cancer
- Venetoclax plus Rituximab an Attractive Treatment Option for Relapsed or Refractory CLL
- Aggressive Local Consolidative Therapy Shows Benefit in Patients with Oligometastatic Non–Small-Cell Lung Cancer
- Lutetium-177-Dotatate Extends Progression-Free Survival in Patients with Midgut Neuroendocrine Tumors
- Inotuzumab Ozogamicin Shows Benefit in Acute Lymphoblastic Leukemia
- Adding Daratumumab to Combination Therapy Improves Progression-Free Survival in Patients with Multiple Myeloma
- Two-Drug Combination Shows Promise for Recurrent Small-Cell Lung Cancer
- Ricolinostat Shows Promise in Patients with Relapsed or Refractory Multiple Myeloma
- Afatinib Superior to Gefitinib as First-Line Treatment for EGFR Mutation–Positive NSCLC
- Combination Chemotherapy plus Radiation Prolongs Survival in Low-Grade Glioma
- Acalabrutinib Demonstrates Efficacy and Safety in Relapsed CLL
- Personalizing Therapy for Patients with Multiple Myeloma
- Targeting BCL2 with Venetoclax in Patients with Relapsed CLL
- Acalabrutinib Demonstrates Efficacy and Safety in Relapsed CLL
- Atezolizumab Shows Durable Response, Tolerability in Urothelial Carcinoma
- Aprepitant Effective in Preventing Chemotherapy-Induced Nausea and Vomiting in Children
- Bevacizumab for Advanced Lung Cancer Does Not Increase Risk for Hospitalization or Unexpected Toxicity
- Daratumumab, an Anti-CD38 Monoclonal Antibody, Effective Treatment Option for Patients with Relapsed and/or Refractory Multiple Myeloma
The current treatment landscape for patients with high-risk localized prostate cancer is predominantly confined to a combination of androgen-deprivation therapy (ADT) plus radiotherapy, which has been shown to improve survival over radiotherapy alone.
We’ve compiled summaries and reviews of four studies dealing with treatments indicated for squamous-cell NSCLC, breast cancer, and neuroendocrine tumors.
We’ve compiled summaries and reviews of three studies dealing with treatments indicated for B-cell cancer, advanced thyroid cancer, and polycythemia vera.
- Anti-CD19 CAR T-Cells Show Promise in B-Cell Cancer
- Lenvatinib Prolongs Progression-Free Survival in Advanced Thyroid Cancer
- Ruxolitinib More Effective Than Standard Therapy in the Treatment of Polycythemia Vera